vericiguat vericiguat vericiguat, sold under the brand name verquvo, is a medication used to reduce the risk of cardiovascular death and hospitalization in certain patients with heart failure after a recent acute decompensation event. it is taken by mouth. vericiguat is a soluble guanylate cyclase (sgc) stimulator. vericiguatclinical datatrade namesverquvolicense data us dailymed: vericiguat pregnancycategory au: d contraindicated routes ofadministrationby mouthdrug classsoluble guanylate cyclase activatoratc codec01dx22 (who) legal statuslegal status au: s4 (prescription only) us: ℞-only eu: rx-only identifiers iupac name methyl n-pyrazolopyridin-3-yl]pyrimidin-5-yl]carbamate cas number1350653-20-1pubchem cid54674461drugbankdb15456chemspider32700337uniilv66adm269keggd11051chebichebi:142432chemblchembl4066936echa infocard100.247.370 chemical and physical dataformulac19h16f2n8o2molar mass426.388 g·mol−13d model (jsmol)interactive image smiles coc(=o)nc1=c(n=c(n=c1n)c2=nn(c3=c2c=c(c=n3)f)cc4=cc=cc=c4f)n inchi inchi=1s/c19h16f2n8o2/c1-31-19(30)25-14-15(22)26-17(27-16(14)23)13-11-6-10(20)7-24-18(11)29(28-13)8-9-4-2-3-5-12(9)21/h2-7h,8h2,1h3,(h,25,30)(h4,22,23,26,27)key:qzfhixarhdbpby-uhfffaoysa-n common side effects include low blood pressure and low red cell count (anemia). it was approved for medical use in the united states in january 2021, and for use in the european union in july 2021. the u.s. food and drug administration considers it to be a first-in-class medication. medical uses vericiguat is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure following a prior hospitalization for heart failure or need for outpatient intravenous diuretics, in adults with symptomatic chronic heart failure and an ejection fraction of less than 45%. adverse effects vericiguat causes harm to the unborn baby and should not be given to pregnant women. it is not known to what extent vericiguat passes into breastmilk; therefore, breastfeeding patients should not take vericiguat. the most common side effects of vericiguat include low blood pressure and anemia. patients taking other soluble guanylate cyclase inhibitors should not take vericiguat. pharmacology vericiguat is a direct stimulator of soluble guanylate cyclase, an important enzyme in vascular smooth muscle cells. specifically, vericiguat binds to the beta-subunit of the target site on the soluble guanylate cyclase enzyme. soluble guanylate cyclase catalyzes the formation of cyclic gmp upon interaction with nitric oxide to activate a number of downstream signaling cascades, which can compensate for defects in this pathway and resulting losses in regulatory myocardial and vascular cellular processes due to cardiovascular complications. pharmacokinetics after vericiguat is administered (100 mg by mouth once daily), the average steady state and cmax and auc for patients with cardiovascular failure is 350 mcg/l and 6,680 mcg/h/l with a tmax of one hour. vericiguat has a positive food effect, and therefore patients are advised to consume food with the drug for an oral bioavailability of 93%. vericiguat is extensively protein bound in plasma. vericiguat is primarily metabolized via phase 2 conjugation reactions, with a minor cyp-mediated oxidative metabolite. the major metabolite is glucuronidated and inactive. the typical half-life profile for patients with heart failure is 30 hours. vericiguat has a decreased clearance in patients with systolic heart failure. history the u.s. food and drug administration (fda) approved vericiguat based on evidence from a clinical trial (nct02861534) which consisted of 5,050 participants aged 23 to 98 years old with worsening heart failure. the trial was conducted at 694 sites in 42 countries in europe, asia, north and south america. the trial enrolled participants with symptoms of worsening heart failure. participants were randomly assigned to receive vericiguat or a placebo pill once a day. neither the participants nor the health care professionals knew if the participants were given vericiguat or placebo pill until after the trial was complete. it was awarded a fast track designation on 19 january 2021. society and culture legal status on 20 may 2021, the committee for medicinal products for human use (chmp) of the european medicines agency (ema) adopted a positive opinion, recommending the granting of a marketing authorization for vericiguat, intended for the treatment of symptomatic chronic heart failure in adults with reduced ejection fraction. the applicant for this medicinal product is bayer ag. vericiguat was approved for medical use in the european union in july 2021.